DEPO Depomed, Inc. (delisted)

Depomed, Inc. (NASDAQ:DEPO) announced that effective July 3, 2018, the Company granted ten newly-hired employees a total of 512,439 restricted stock units (“RSUs”).  The RSUs were granted as inducements material to each such individual’s entry into employment with Depomed in accordance with NASDAQ Listing Rule 5635(c)(4).  The RSUs are subject to such employee’s continued service relationship with the Company, the terms and conditions of the Company's 2014 Omnibus Incentive Plan and the award agreements pursuant to which they were granted. The RSUs vest equally annually over three years beginning on the anniversary of each individual’s applicable employment commencement date.

About DepomedDepomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.

INVESTOR AND MEDIA CONTACTS:

John B. ThomasSVP, Investor Relations and Corporate Communicationsjthomas@depomed.com